Genprex Collaborators Selected To Present Preclinical Data On The Use Of Reqorsa Gene Therapy At The 2024 EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Genprex, Inc. announced that its collaborators will present preclinical data on Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium. The data focuses on treating Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma.
September 09, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex's Reqorsa Gene Therapy will be presented at a major symposium, showcasing its potential in treating resistant cancers. This could boost investor confidence and impact stock prices positively.
The presentation of positive preclinical data at a prestigious symposium can enhance the visibility and perceived value of Genprex's lead drug candidate, potentially leading to increased investor interest and a positive impact on stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100